切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2025, Vol. 14 ›› Issue (02) : 197 -202. doi: 10.3877/cma.j.issn.2095-3232.2025027

专家论坛

钇90选择性内放射治疗肝内胆管癌的现状与展望
刘康寿1, 曹明溶1, 孙健1,()   
  1. 1. 510630 广州,暨南大学附属第一医院肝胆外科
  • 收稿日期:2024-12-18 出版日期:2025-04-10
  • 通信作者: 孙健
  • 基金资助:
    广东省基础与应用基础研究基金项目(2022A1515012581)

Current status and prospect of selective internal radiotherapy with yttrium-90 for intrahepatic cholangiocarcinoma

Kangshou Liu1, Mingrong Cao1, Jian Sun1,()   

  1. 1. Department of Hepatobiliary Surgery, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China
  • Received:2024-12-18 Published:2025-04-10
  • Corresponding author: Jian Sun
引用本文:

刘康寿, 曹明溶, 孙健. 钇90选择性内放射治疗肝内胆管癌的现状与展望[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 197-202.

Kangshou Liu, Mingrong Cao, Jian Sun. Current status and prospect of selective internal radiotherapy with yttrium-90 for intrahepatic cholangiocarcinoma[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 197-202.

肝内胆管癌(ICC)是继肝细胞癌之后第二常见的原发性肝癌,大部分患者为中晚期,只能接受系统治疗及局部治疗。近年来,钇90 选择性内放射治疗在肝恶性肿瘤上的治疗效果得到国内外的公认,已成为肝恶性肿瘤局部治疗的重要方式,相关临床研究也已证明其在肝恶性肿瘤治疗上的有效性及安全性。本综述对钇90 选择性内放射治疗ICC 的最新文献进行回顾,总结钇90 选择性内放射治疗在ICC 单独治疗以及联合化疗、放射性肝段/叶切除治疗、肝移植治疗的安全性、有效性和实用性。

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer secondary to hepatocellular carcinoma.Most patients are diagnosed in the middle and late stage and can only receive systematic and local treatments.In recent years, the therapeutic effect of selective internal radiotherapy with yttrium-90 for malignant liver tumors has been widely recognized at home and abroad,and it has become an important local treatment for malignant liver tumors.It’s effectiveness and safety in the treatment of malignant liver tumors have been validated by relevant clinical studies.In this article, the latest literature review of selective internal radiotherapy with yttrium-90 for ICC was conducted, and the safety, effectiveness and practicability of selective internal radiotherapy with yttrium-90 as a single option,combined with chemotherapy, radiation segmentectomy/hepatectomy and liver transplantation for ICC were summarized.

[1]
Siegel R, Naishadham D, Jemal A.Cancer statistics, 2013[J].CA A Cancer J Clin, 2013, 63(1): 11-30.DOI: 10.3322/caac.21166.
[2]
Beal EW, Tumin D, Moris D, et al.Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma[J].Hepatobiliary Surg Nutr, 2018, 7(4): 270-276.DOI: 10.21037/hbsn.2018.03.16.
[3]
Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2018, 68(6): 394-424.DOI: 10.3322/caac.21492.
[4]
Labib PL, Goodchild G, Pereira SP.Molecular pathogenesis of cholangiocarcinoma[J].BMC Cancer, 2019, 19(1): 185.DOI: 10.1186/s12885-019-5391-0.
[5]
Khan SA, Tavolari S, Brandi G.Cholangiocarcinoma: epidemiology and risk factors[J].Liver Int, 2019, 39(Suppl 1): 19-31.DOI: 10.1111/liv.14095.
[6]
Welzel TM, Graubard BI, El-Serag HB, et al.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States:a population-based case-control study[J].Clin Gastroenterol Hepatol,2007, 5(10): 1221-1228.DOI: 10.1016/j.cgh.2007.05.020.
[7]
Welzel TM, Mellemkjaer L, Gloria G, et al.Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide casecontrol study[J].Int J Cancer, 2007, 120(3): 638-641.DOI: 10.1002/ijc.22283.
[8]
中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO):胆道恶性肿瘤诊疗指南2023[M].北京: 人民卫生出版社, 2023.Guideline working committee of the Chinese Society of clinical Oncolgy.Chinese Society of Clinical Oncology (csco): diagnosis and treatment guidelines for biliary maliqnant tumors 2023 [M].Beijing:People’s Health Publishing House, 2023.
[9]
Valle J, Wasan H, Palmer DH, et al.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J].N Engl J Med, 2010, 362(14):1273-1281.DOI: 10.1056/NEJMoa0908721.
[10]
Oh DY, He AR, Qin S, et al.Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer[J].NEJM Evid, 2022, 1(8):EVIDoa2200015.DOI: 10.1056/EVIDoa2200015.
[11]
Oh D, He AR, Qin S, et al.Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)[J].Ann Oncol, 2022, 33(suppl 7): 565-S566.DOI: 10.1016/j.annnonc.2022.07.084.
[12]
Hickey RM, Lewandowski RJ, Salem R.Yttrium-90 radioembolization for hepatocellular carcinoma[J].Semin Nucl Med, 2016,46(2): 105-108.DOI: 10.1053/j.semnuclmed.2015.10.011.
[13]
Westcott MA, Coldwell DM, Liu DM, et al.The development,commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres[J].Adv Radiat Oncol, 2016, 1(4): 351-364.DOI: 10.1016/j.adro.2016.08.003.
[14]
Andrews JC, Walker SC, Ackermann RJ, et al.Hepatic radioembolization with yttrium-90 containing glass microspheres:preliminary results and clinical follow-up[J].J Nucl Med, 1994,35(10): 1637-1644.
[15]
Dancey JE, Shepherd FA, Paul K, et al.Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres[J].J Nucl Med, 2000, 41(10): 1673-1681.
[16]
Houle S, Yip TK, Shepherd FA, et al.Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres[J].Radiology, 1989, 172(3):857-860.DOI: 10.1148/radiology.172.3.2549567.
[17]
Fernandez-Ros N, Iñarrairaegui M, Paramo JA, et al.Radioembolization of hepatocellular carcinoma activates liver regeneration,induces inflammation and endothelial stress and activates coagulation[J].Liver Int, 2015, 35(5): 1590-1596.DOI: 10.1111/liv.12592.
[18]
Chew V, Lee YH, Pan L, et al.Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma[J].Gut, 2019, 68(2): 335-346.DOI: 10.1136/gutjnl-2017-315485.
[19]
Robinson TJ, Du L, Matsuoka L, et al.Survival and toxicities after yttrium-90 transarterial radioembolization of cholangiocarcinoma in the RESiN registry[J].J Vasc Interv Radiol, 2023, 34(4): 694-701.e3.DOI: 10.1016/j.jvir.2022.10.042.
[20]
Mosconi C, Cacioppa LM, Cappelli A, et al.Update of the bologna experience in radioembolization of intrahepatic cholangiocarcinoma[J].Technol Cancer Res Treat, 2023, 22: 15330338231155690.DOI:10.1177/15330338231155690.
[21]
Edeline J, Touchefeu Y, Guiu B, et al.Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial[J].JAMA Oncol, 2020,6(1): 51-59.DOI: 10.1001/jamaoncol.2019.3702.
[22]
Chan SL, Chotipanich C, Choo SP, et al.Selective internal radiation therapy with yttrium-90 resin microspheres followed by gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma: a phase 2 single-arm multicenter clinical trial[J].Liver Cancer, 2022,11(5): 451-459.DOI: 10.1159/000525489.
[23]
Yu Q, Liu C, Pillai A, et al.Twenty years of radiation therapy of unresectable intrahepatic cholangiocarinoma: internal or external? A systematic review and meta-analysis[J].Liver Cancer, 2021, 10(5):433-450.DOI: 10.1159/000516880.
[24]
Riaz A, Gates VL, Atassi B, et al.Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization[J].Int J Radiat Oncol Biol Phys, 2011, 79(1): 163-171.DOI: 10.1016/j.ijrobp.2009.10.062.
[25]
Vouche M, Habib A, Ward TJ, et al.Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation:multicenter radiology-pathology correlation and survival of radiation segmentectomy[J].Hepatology, 2014, 60(1): 192-201.DOI: 10.1002/hep.27057.
[26]
Paz-Fumagalli R, Core J, Padula C, et al.Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma[J].Oncotarget, 2021, 12(20): 2075-2088.DOI: 10.18632/oncotarget.28060.
[27]
Filippi L, Di Costanzo GG, Tortora R, et al.Repeated treatment with 90Y-microspheres in intrahepatic cholangiocarcinoma relapsed after the first radioembolization[J].Cancer Biother Radiopharm, 2019, 34(4):231-237.DOI: 10.1089/cbr.2018.2718.
[28]
Hand F, Hoti E.Contemporary role of liver transplantation for the treatment of cholangiocarcinoma[J].Expert Rev Gastroenterol Hepatol,2020, 14(6): 475-481.DOI: 10.1080/17474124.2020.1765771.
[29]
Sapisochin G, Facciuto M, Rubbia-Brandt L, et al.Liver transplantation for “very early” intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment[J].Hepatology, 2016, 64(4): 1178-1188.DOI: 10.1002/hep.28744.
[30]
Lunsford KE, Javle M, Heyne K, et al.Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series[J].Lancet Gastroenterol Hepatol,2018, 3(5): 337-348.DOI: 10.1016/S2468-1253(18)30045-1.
[31]
Lopez-Lopez V, Miura K, Kuemmerli C, et al.Selecting the appropriate downstaging and bridging therapies for hepatocellular carcinoma: what is the role of transarterial radioembolization?A pooled analysis[J].Cancers, 2023, 15(7): 2122.DOI: 10.3390/cancers15072122.
[32]
Gabr A, Kulik L, Mouli S, et al.Liver transplantation following yttrium-90 radioembolization: 15-year experience in 207-patient cohort[J].Hepatology, 2021, 73(3): 998-1010.DOI: 10.1002/hep.31318.
[33]
吴添庆,王炯亮,郑梽楷,等.经动脉放疗栓塞术治疗不可切除肝内胆管细胞癌疗效与安全性Meta分析[J/OL].中华肝脏外科手术学电子杂志,2023,12(2):190-195.DOI:10.3877/cma.j.issn.2095-3232.2023.02.013.Wu TQ, Wang JL, Zheng ZK, et al.Efffcacy and safety of transarterial radioembolization for unresectable intrahepatic cholangiocarcinoma:a Meta-analysis[J/OL].Chin J Hepat Surg(Electronic Edition), 2023,12(2): 190-195.DOI:10.3877/cma.j.issn.2095-3232.2023.02.013.
[1] 周金龙, 刘俊杰, 谷昊. 淋巴结清扫对肝内胆管癌预后价值的Meta分析[J/OL]. 中华普通外科学文献(电子版), 2023, 17(02): 155-160.
[2] 郭俊标, 李绍强, 宋泽兵, 黄力, 胡文杰. 区域淋巴结清扫对肝内胆管癌根治术后复发模式的影响[J/OL]. 中华普通外科学文献(电子版), 2022, 16(02): 97-100.
[3] 张小松, 马俊永, 李锡锋, 施乐华, 沈锋. 腹腔镜鞘内解剖性右半肝切除联合区域淋巴结清扫[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(03): 245-245.
[4] 丁志文, 赵一鸣, 王鲁. 肝内胆管癌手术与综合治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 187-196.
[5] 陈明政, 栗玉龙, 唐流康, 谢峰. IDH1突变应用于肝内胆管癌治疗的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(01): 103-108.
[6] 赵晓飞, 栗光明. 肝内胆管细胞癌的诊治[J/OL]. 中华肝脏外科手术学电子杂志, 2021, 10(01): 6-9.
[7] 童焕军, 汤朝晖, 全志伟. 肝内胆管癌异常脂质代谢研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2020, 09(06): 501-506.
[8] 苏淼, 赵东强. 肝内胆管癌预后因素的研究进展[J/OL]. 中华胃肠内镜电子杂志, 2023, 10(01): 62-66.
阅读次数
全文


摘要